MicroRNAs-based therapeutic strategy for virally induced diseases

Alhousseynou Sall, Zhen Liu, Huifang M. Zhang, Ji Yuan, Travis Lim, Yue Su, Decheng Yang

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) are endogenous, short, double-stranded and noncoding RNA molecules that have been identified in a variety of organisms and certain viruses. This group of new molecules is transcribed mainly from the introns and/or exons or intergenic regions and plays important regulatory roles in development and gene expression. Mature miRNAs are typically 20-24 nucleotides in length and regulate target mRNAs post transcriptionally by interactions with partially mismatched sequences in the 3′untraslated regions of these messengers. These interactions result in the suppression of translation or degradation of target mRNAs. At the present, although the biological functions of miRNAs are not completely revealed, a growing body of evidence implicates that miRNA pathway is a new mechanism of gene regulation in both normal and diseased conditions and therefore investigation of miRNA biogenesis and function may add new tools for gene functional study and drug development. In this article, we will briefly review the structure, biogenesis and basic mechanism of action of miRNAs identified in higher organisms and viruses and then focus on the recent progress in research for drug development using the miRNA pathway as a strategy. Particularly, we will discuss the advance, challenge and future directions on antiviral drug development using miRNA as a target or a gene silencing tool for the treatment of viral infections.

Original languageEnglish (US)
Pages (from-to)49-58
Number of pages10
JournalCurrent drug discovery technologies
Volume5
Issue number1
DOIs
StatePublished - Mar 1 2008

Fingerprint

MicroRNAs
Therapeutics
Viruses
Untranslated RNA
Intergenic DNA
Double-Stranded RNA
RNA Stability
Gene Silencing
Virus Diseases
Pharmaceutical Preparations
Introns
Genes
Antiviral Agents
Exons
Nucleotides
Gene Expression
Messenger RNA
Research

Keywords

  • Antisense oligonucleotides
  • Gene regulation antiviral
  • RNAi
  • Therapeutics
  • miRNA
  • siRNA

ASJC Scopus subject areas

  • Drug Discovery

Cite this

MicroRNAs-based therapeutic strategy for virally induced diseases. / Sall, Alhousseynou; Liu, Zhen; Zhang, Huifang M.; Yuan, Ji; Lim, Travis; Su, Yue; Yang, Decheng.

In: Current drug discovery technologies, Vol. 5, No. 1, 01.03.2008, p. 49-58.

Research output: Contribution to journalReview article

Sall, Alhousseynou ; Liu, Zhen ; Zhang, Huifang M. ; Yuan, Ji ; Lim, Travis ; Su, Yue ; Yang, Decheng. / MicroRNAs-based therapeutic strategy for virally induced diseases. In: Current drug discovery technologies. 2008 ; Vol. 5, No. 1. pp. 49-58.
@article{e871df7e177144cbae887e287eda33e2,
title = "MicroRNAs-based therapeutic strategy for virally induced diseases",
abstract = "MicroRNAs (miRNAs) are endogenous, short, double-stranded and noncoding RNA molecules that have been identified in a variety of organisms and certain viruses. This group of new molecules is transcribed mainly from the introns and/or exons or intergenic regions and plays important regulatory roles in development and gene expression. Mature miRNAs are typically 20-24 nucleotides in length and regulate target mRNAs post transcriptionally by interactions with partially mismatched sequences in the 3′untraslated regions of these messengers. These interactions result in the suppression of translation or degradation of target mRNAs. At the present, although the biological functions of miRNAs are not completely revealed, a growing body of evidence implicates that miRNA pathway is a new mechanism of gene regulation in both normal and diseased conditions and therefore investigation of miRNA biogenesis and function may add new tools for gene functional study and drug development. In this article, we will briefly review the structure, biogenesis and basic mechanism of action of miRNAs identified in higher organisms and viruses and then focus on the recent progress in research for drug development using the miRNA pathway as a strategy. Particularly, we will discuss the advance, challenge and future directions on antiviral drug development using miRNA as a target or a gene silencing tool for the treatment of viral infections.",
keywords = "Antisense oligonucleotides, Gene regulation antiviral, RNAi, Therapeutics, miRNA, siRNA",
author = "Alhousseynou Sall and Zhen Liu and Zhang, {Huifang M.} and Ji Yuan and Travis Lim and Yue Su and Decheng Yang",
year = "2008",
month = "3",
day = "1",
doi = "10.2174/157016308783769478",
language = "English (US)",
volume = "5",
pages = "49--58",
journal = "Current Drug Discovery Technologies",
issn = "1570-1638",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - MicroRNAs-based therapeutic strategy for virally induced diseases

AU - Sall, Alhousseynou

AU - Liu, Zhen

AU - Zhang, Huifang M.

AU - Yuan, Ji

AU - Lim, Travis

AU - Su, Yue

AU - Yang, Decheng

PY - 2008/3/1

Y1 - 2008/3/1

N2 - MicroRNAs (miRNAs) are endogenous, short, double-stranded and noncoding RNA molecules that have been identified in a variety of organisms and certain viruses. This group of new molecules is transcribed mainly from the introns and/or exons or intergenic regions and plays important regulatory roles in development and gene expression. Mature miRNAs are typically 20-24 nucleotides in length and regulate target mRNAs post transcriptionally by interactions with partially mismatched sequences in the 3′untraslated regions of these messengers. These interactions result in the suppression of translation or degradation of target mRNAs. At the present, although the biological functions of miRNAs are not completely revealed, a growing body of evidence implicates that miRNA pathway is a new mechanism of gene regulation in both normal and diseased conditions and therefore investigation of miRNA biogenesis and function may add new tools for gene functional study and drug development. In this article, we will briefly review the structure, biogenesis and basic mechanism of action of miRNAs identified in higher organisms and viruses and then focus on the recent progress in research for drug development using the miRNA pathway as a strategy. Particularly, we will discuss the advance, challenge and future directions on antiviral drug development using miRNA as a target or a gene silencing tool for the treatment of viral infections.

AB - MicroRNAs (miRNAs) are endogenous, short, double-stranded and noncoding RNA molecules that have been identified in a variety of organisms and certain viruses. This group of new molecules is transcribed mainly from the introns and/or exons or intergenic regions and plays important regulatory roles in development and gene expression. Mature miRNAs are typically 20-24 nucleotides in length and regulate target mRNAs post transcriptionally by interactions with partially mismatched sequences in the 3′untraslated regions of these messengers. These interactions result in the suppression of translation or degradation of target mRNAs. At the present, although the biological functions of miRNAs are not completely revealed, a growing body of evidence implicates that miRNA pathway is a new mechanism of gene regulation in both normal and diseased conditions and therefore investigation of miRNA biogenesis and function may add new tools for gene functional study and drug development. In this article, we will briefly review the structure, biogenesis and basic mechanism of action of miRNAs identified in higher organisms and viruses and then focus on the recent progress in research for drug development using the miRNA pathway as a strategy. Particularly, we will discuss the advance, challenge and future directions on antiviral drug development using miRNA as a target or a gene silencing tool for the treatment of viral infections.

KW - Antisense oligonucleotides

KW - Gene regulation antiviral

KW - RNAi

KW - Therapeutics

KW - miRNA

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=40549105741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40549105741&partnerID=8YFLogxK

U2 - 10.2174/157016308783769478

DO - 10.2174/157016308783769478

M3 - Review article

C2 - 18537567

AN - SCOPUS:40549105741

VL - 5

SP - 49

EP - 58

JO - Current Drug Discovery Technologies

JF - Current Drug Discovery Technologies

SN - 1570-1638

IS - 1

ER -